These participants described some degree of benefit from a period of improved HRQoL, allowing them to perform more daily activities and tasks than they normally would have done, especially if it was for a significant period of time (e.g. longer than 6 months, as was pointed out by one of the participants with HR+/HER2− breast cancer). This evidence concerns the gene HR and breast cancer.